The influence of particle physicochemical properties on delivery of drugs by dry powder inhalers to the lung

Drug Delivery

Volumn , Issue , 2011, Pages 1-49

  Nokhodchi, Ali ^a,b   Kaialy, Waseem ^a,c   Ticehurst, Martyn D ^d  

^a MEDWAY SCHOOL OF PHARMACY   (United Kingdom)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c DAMASCUS UNIVERSITY   (Syrian Arab Republic)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84856549198     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (293)

1. Adams, W.P., Christopher, D., Lee, D.S., Morgan, B., Pan, Z., Singh, G.J.P., Tsong, Y. and Lyapustina, S. 2007. Product Quality Research Institute evaluation of cascade impactor profiles of pharmaceutical aerosols, Part 1: background for a statistical method. AAPS PharmSciTech, 8, 32-37.
2. Adi, H., Larson, I. and Stewart, P.J. 2007. Adhesion and redistribution of salmeterol xinafoate particles in sugar-based mixtures for inhalation. International journal of pharmaceutics, 337, 229-238.
3. Adjei, A.L., Qiu, Y. and Gupta, P.K. 1996. Bioavailability and pharmacokinetics of inhaled drugs. Lung biology in health and disease, 94, 197-231.
4. Agnew, JE. Physical properties and mechanisms of deposition of aerosols. Aerosols and the lung. In: Clarke SW, Pavia D. Aerosols and the Lung: Clinical and Experimental Aspects. London, UK: Butterworth and Co. Ltd; 1984; 49-70.
5. Ahfat, N.M., Buckton, G., Burrows, R. and Ticehurst, M.D. 1997. Predicting mixing performance using surface energy measurements. International journal of pharmaceutics, 156, 89-95.
6. Alexander, A., Shinbrot, T., Johnson, B. and Muzzio, F.J. 2004. V-blender segregation patterns for free-flowing materials: effects of blender capacity and fill level. International journal of pharmaceutics, 269, 19-28.
7. Allen, T. Particle Size Measurement. 4th edition. London: Chapman and Hall; 1990.
8. Altiere, R.J. and Thompson, D.C. 1996, "Physiology and pharmacology of the airways", Lung Biology in Health and Disease, vol. 94, pp. 85-137.
9. Ashurst, I., Malton, A., Prime, D. and Sumby, B. 2000. Latest advances in the development of dry powder inhalers. Pharmaceutical science and technology today, 3, 246-256.
10. Atkins, P. and Clark, A.R. 1994. Drug delivery to the respiratory tract and drug dosimetry. Journal of aerosol medicine, 7, 33-38.
11. Aulton, ME. Aulton's pharmaceutics: the design and manufacture of medicines. 3rd Edition. Edinburgh: Churchill Livingstone; 2007.
12. Bailey, A.G. 1984. Electrostatic phenomena during powder handling. Powder echnology, 37, 71-85.
13. Bakan, JL, Anderson, JL. Microencapsulation. In: Lachman L, Lieberman HA, Kanig JL. The Theory and Practice of Industrial Pharmacy. Philadelphia: Lea and Febiger; 1978; 412-429.
14. Baron, PA, Willeke, K. 4 Gas and Particle Motion. In: Baron PA, Willeke K. Aerosol measurement: principles, techniques, and applications. New York: John Wiley and Sons; 2001; 61-82
15. Beach, S., Latham, D., Sidgwick, C., Hanna, M. and York, P. 1999. Control of the physical form of salmeterol xinafoate. ACS Publications, 3, 370-376
16. Bechtold-Peters, K., Nguyen, H. and Rowley, G. 2002. Surface modification of powders with fatty acid or fatty alcohol derivatives or poloxamer for inhalation, PCT Int, Appl. 20021017.
17. Begat, P., Morton, D.A.V., Staniforth, J.N. and Price, R. 2004b. The cohesive-adhesive balances in dry powder inhaler formulations II: Influence on fine particle delivery characteristics. Pharmaceutical research, 21, 1826-1833.
18. Begat, P., Morton, D.A.V., Staniforth, J.N. and Price, R. 2004a. The cohesive-adhesive balances in dry powder inhaler formulations I: Direct quantification by atomic force microscopy. Pharmaceutical research, 21, 1591-1597.
19. Begat, P., Price, R., Harris, H., Morton, D.A.V. and Staniforth, J.N. 2005. The influence of force control agents on the cohesive-adhesive balance in dry powder inhaler formulations. Kona, 23, 109-121.
20. Bell, J., Hartley, P. and Cox, J. 2006. Dry powder aerosols I: a new powder inhalation device. Journal of pharmaceutical sciences, 60, 1559-1564.
21. Ben-Jebria, A., Chen, D., Eskew, M.L., Vanbever, R., Langer, R. and Edwards, D.A. 1999. Large porous particles for sustained protection from carbachol-induced bronchoconstriction in guinea pigs. Pharmaceutical research, 16, 555-561.
22. Berard, V., Lesniewska, E., Andres, C., Pertuy, D., Laroche, C. and Pourcelot, Y. 2002. Dry powder inhaler: influence of humidity on topology and adhesion studied by AFM. International journal of pharmaceutics, 232, 213-224.
23. Berkovitch-Yellin, Z. 1985. Toward an ab initio derivation of crystal morphology. Journal of the American Chemical Society, 107, 8239-8253.
24. Borgstrom, L., Derom, E., Stahl, E., Wahlin-Boll, E. and Pauwels, R. 1996. The inhalation device influences lung deposition and bronchodilating effect of terbutaline. American journal of respiratory and critical care medicine, 153, 1636.
25. Bosquillon, C., Lombry, C., Preat, V. and Vanbever, R. 2001. Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance, Journal of Controlled Release, 70, 329-339.
26. Bosquillon, C., Rouxhet, P.G., Ahimou, F., Simon, D., Culot, C., Préat, V. and Vanbever, R. 2004. Aerosolization properties, surface composition and physical state of spray-dried protein powders. Journal of Controlled Release, 99, 357-367.
27. Brain, JD, Blanchard JD. Mechanisms of particle deposition and clearance. In: Moren F, Dolovich M, Newhouse MT, Newman SP. Aerosols in medicine: principles, diagnosis and therapy. Amsterdam: Elsevier Science; 1993; 117-156.
28. Brain, J.D. and Valberg, P.A. 1979. Deposition of aerosol in the respiratory tract. The American Review of Respiratory Disease, 120, 1325-1373.
29. Braun, M.A., Oschmann, R. and Schmidt, P. 1996. Influence of excipients and storage humidity on the deposition of disodium cromoglycate (DSCG) in the twin impinge. International journal of pharmaceutics, 135, 53-62.
30. Bridson, R.H., Robbins, P.T., Chen, Y., Westerman, D., Gillham, C.R., Roche, T.C. and Seville, J.P.K. 2007. The effects of high shear blending on [alpha]-lactose monohydrate. International journal of pharmaceutics, 339, 84-90.
31. Brittain, H. Polymorphism in pharmaceutical solids. 1st edition. New York: Dekker; 1999.
32. Buckton, G. 1997. Characterization of small changes in the physical properties of powders of significance for dry powder inhaler formulations. Advanced Drug Delivery Reviews, 26, 17-27.
33. Byron, P.R. 1986. Some future perspectives for unit dose inhalation aerosols. Drug development and industrial pharmacy, 12, 993-1015.
34. Byron, P.R. and Jashnam, R. 1990. Efficiency of Aerosolization from Dry Powder Blends of Terbutaline Sulfate and Lactose NF with Different Particle-Size Distributions. Pharmaceutical Research, 7, 881.
35. Carr, R.L. 1965b. Evaluating flow properties of solids. Chemical engineering, 72, 163-168.
36. Carr, R.L. 1965a. Classifying flow properties of solids. Chemical engineering, 72, 68-72.
37. Carstensen, JT. Pharmaceutical Principles of Solid Dosage Forms. 1st edition. Lancaster; PA: Technomic Pub; 1993
38. Carstensen, JT, Carstensen, JT. Pharmaceutics of solids and solid dosage forms. 1st edition. New York: Wiley, 1977
39. Cegla, U.H. 2004. Pressure and inspiratory flow characteristics of dry powder inhalers. Respiratory medicine, 98, S22-S28.
40. Chan, H.K. 2006. Dry powder aerosol delivery systems: current and future research directions. Journal of Aerosol Medicine, 19, 21-27.
41. Chan, H.K. 2003. Inhalation drug delivery devices and emerging technologies, 13, 1333-1343.
42. Chan, T.L. and Lippmann, M. 1980. Experimental measurements and empirical modelling of the regional deposition of inhaled particles in humans. American Industrial Hygiene Association Journal, 41, 399-409.
43. Chew, N.Y.K., Bagster, D.F. and Chan, H.K. 2000. Effect of particle size, air flow and inhaler device on the aerosolisation of disodium cromoglycate powders. International journal of pharmaceutics, 206, 75-83.
44. Chew, N.Y.K. and Chan, H.K. 2001. Use of solid corrugated particles to enhance powder aerosol performance. Pharmaceutical research, 18, 1570-1577.
45. Chew, N.Y.K. and Chan, H.K. 1999. Influence of particle size, air flow, and inhaler device on the dispersion of mannitol powders as aerosols. Pharmaceutical research, 16, 1098-1103.
46. Chew, N.Y.K., Shekunov, B.Y., Tong, H.H.Y., Chow, A.H.L., Savage, C., Wu, J. and Chan, H.K. 2005a. Effect of amino acids on the dispersion of disodium cromoglycate powders. Journal of pharmaceutical sciences, 94, 2289-2300.
47. Chew, N.Y.K., Tang, P., Chan, H.K. and Raper, J.A. 2005b. How much particle surface corrugation is sufficient to improve aerosol performance of powders?. Pharmaceutical research, 22, 148-152.
48. Clark, A, Borgstrom, L. In vitro testing of pharmaceutical aerosols and predicting lung deposition from in vitro measurements. In: Bisgaard H, O'callaghan C, and Smalldone GC. Drug Delivery to the Lung. New York: Marcel Dekker; 2002; 105-142.
49. Clarke, M.J., Tobyn, M.J. and Staniforth, J.N. 2001. The formulation of powder inhalation systems containing a high mass of nedocromil sodium trihydrate. Journal of pharmaceutical sciences, 90, 213-223.
50. Clay, M.M., Pavia, D. and Clarke, S.W. 1986. Effect of aerosol particle size on bronchodilatation with nebulised terbutaline in asthmatic subjects. Thorax, 41, 364.
51. Clay, M.M., Pavia, D., Newman, S.P. and Clarke, S.W. 1983. Factors influencing the size distribution of aerosols from jet nebulisers. Thorax, 38, 755-759.
52. Cline, D. and Dalby, R. 2002. Predicting the quality of powders for inhalation from surface energy and area. Pharmaceutical research, 19, 1274-1277.
53. Colombo, P, Catellani, PL, Massimo, G, Santi, P, Bettini, R, Cocconi, D, Cagnani, S, Ventura, P. Surface smoothing of lactose particles for dry powder inhalers. In: Dalby RN, Byron PR, Farr SJ, Peart J. Respiratory Drug Delivery VII. Raleigh, England: Serentec Press; 2000; 629-632.
54. Concessio, N.M., VanOort, M.M. and Hickey, A.J. 1998. Impact Force Separation Measurements-Their Relevance in Powder Aerosol Formulation. Respiratory drug delivery, 6, 251-258.
55. Crooks, PA, Damani, LA. Drug application to the respiratory tract: metabolic and pharmacokinetic considerations. In: Byron PR. Respiratory Drug Delivery. Boca Raton, FL: CRC Press; 1989; 61-90.
56. Dalby, R.N., Tiano, S.L. and Hickey, A.J. 1996. Medical devices for the delivery of therapeutic aerosols to the lungs. Lung biology in health and disease, 94, 441-473.
57. Davies, C.N. 1979. Particle-fluid interaction. Journal of Aerosol Science, 10, 477-513.
58. De Boer, A.H., Hagedoorn, P., Kussendrager, K., Dickhoff, B.H.J. and Frijlink, H.W. 2002b. Investigating the relevant parameters for the performance of adhesive mixtures in an air classifier during inhalation. Drug Delivery to the Lungs XIII, 10, 7-10.
59. De Boer, A.H., Gjaltema, D., Hagedoorn, P. and Frijlink, H.W. 2002a. Characterization of inhalation aerosols: a critical evaluation of cascade impactor analysis and laser diffraction technique. International journal of pharmaceutics, 249, 219-231.
60. De Boer, A.H., Hagedoorn, P., Gjaltema, D., Goede, J. and Frijlink, H.W. 2006. Air classifier technology (ACT) in dry powder inhalation: Part 4. Performance of air classifier technology in the Novolizer® multi-dose dry powder inhaler. International journal of pharmaceutics, 310, 81-89.
61. De Boer, A.H., Hagedoorn, P., Gjaltema, D., Goede, J. and Frijlink, H.W. 2003. Air classifier technology (ACT) in dry powder inhalation: Part 1. Introduction of a novel force distribution concept (FDC) explaining the performance of a basic air classifier on adhesive mixtures. International journal of pharmaceutics, 260, 187-200.
62. de Villiers, M.M. 1997. Description of the kinetics of the deagglomeration of drug particle agglomerates during powder mixing. International journal of pharmaceutics, 151, 1-6.
63. Dhumal, R.S., Biradar, S.V., Paradkar, A.R. and York, P. 2009. Particle engineering using sonocrystallization: Salbutamol sulphate for pulmonary delivery", International journal of pharmaceutics, 368, 129-137.
64. Di Martino, P., Censi, R., Malaj, L., Capsoni, D., Massarotti, V. and Martelli, S. 2007. Influence of solvent and crystallization method on the crystal habit of metronidazole. Crystal Research and Technology, 42, 800-806.
65. Dickhoff, B.H.J., de Boer, A.H., Lambregts, D. and Frijlink, H.W. 2006. The effect of carrier surface treatment on drug particle detachment from crystalline carriers in adhesive mixtures for inhalation. International journal of pharmaceutics, 327, 17-25.
66. Dickhoff, B.H.J., de Boer, A.H., Lambregts, D. and Frijlink, H.W. 2005b. The effect of carrier rugosity on drug particle detachment during inhalation, in relation to carrier size and mixing intensity at low carrier payloads. Dissertations.ub.rug.nl, 97-101
67. Dickhoff, B.H.J., De Boer, A.H., Lambregts, D. and Frijlink, H.W. 2005a. The interaction between carrier rugosity and carrier payload, and its effect on drug particle redispersion from adhesive mixtures during inhalation. European Journal of Pharmaceutics and Biopharmaceutics, 59, 197-205.
68. Dickhoff, B.H.J., de Boer, A.H., Lambregts, D. and Frijlink, H.W. 2003. The effect of carrier surface and bulk properties on drug particle detachment from crystalline lactose carrier particles during inhalation, as function of carrier payload and mixing time. European journal of pharmaceutics and biopharmaceutics, 56, 291-302.
69. Ducker, W.A., Senden, T.J. and Pashley, R.M. 1991. Direct measurement of colloidal forces using an atomic force microscope. Nature, 353, 239-241.
70. Duddu, S.P., Sisk, S.A., Walter, Y.H., Tarara, T.E., Trimble, K.R., Clark, A.R., Eldon, M.A., Elton, R.C., Pickford, M. and Hirst, P.H. 2002. Improved lung delivery from a passive dry powder inhaler using an engineered PulmoSphere® powder. Pharmaceutical research, 19, 689-695.
71. Dunbar, C.A., Hickey, A.J. and Holzner, P. 1998. Dispersion and characterization of pharmaceutical dry powder aerosols. Kona, 16, 7-45.
72. Dunbar, C.A., Morgan, B., Van Oort, M. and Hickey, A.J. 2000. A Comparison of Dry Powder Inhaler Dose Delivery Characteristics Using a Power Criterion. PDA Journal of Pharmaceutical Science and Technology, 54, 478-484.
73. Edwards, D.A. and Dunbar, C. 2002. Bioengineering of therapeutic aerosols. Annual Review of Biomedical Engineering, 4, 93-107.
74. Edwards, D.A., Hanes, J., Caponetti, G., Hrkach, J., Ben-Jebria, A., Eskew, M.L., Mintzes, J., Deaver, D., Lotan, N. and Langer, R. 1997. Large porous particles for pulmonary drug delivery. Science, 276, 1868-1872.
75. Eerikäinen, H., Watanabe, W., Kauppinen, E.I. and Ahonen, P. 2003. Aerosol flow reactor method for synthesis of drug nanoparticles. European journal of pharmaceutics and biopharmaceutics, 55, 357-360.
76. El-Hagrasy, A.S., Morris, H.R., D'Amico, F., Lodder, R.A. and Drennen, J.K. 2001. Near-infrared spectroscopy and imaging for the monitoring of powder blend homogeneity. Journal of pharmaceutical sciences, 90, 1298-1307.
77. El-Sabawi, D., Price, R., Edge, S. and Young, P.M. 2006. Novel temperature controlled surface dissolution of excipient particles for carrier based dry powder inhaler formulations. Drug development and industrial pharmacy, 32, 243-251.
78. Elversson, J., Millqvist-Fureby, A., Alderborn, G. and Elofsson, U. 2003. Droplet and particle size relationship and shell thickness of inhalable lactose particles during spray drying. Journal of pharmaceutical sciences, 92, 900-910.
79. Ely, L., Roa, W., Finlay, W.H. and Löbenberg, R. 2007. Effervescent dry powder for respiratory drug delivery. European Journal of Pharmaceutics and Biopharmaceutics, 65, 346-353.
80. Eve, J.K., Patel, N., Luk, S.Y., Ebbens, S.J. and Roberts, C.J. 2002. A study of single drug particle adhesion interactions using atomic force microscopy. International journal of pharmaceutics, 238, 17-27.
81. Feeley, J.C. 2002. Powder characterization tests: Can they make a difference in product development. Respiratory drug delivery, 1, 295-301.
82. Feeley, J.C., York, P., Sumby, B.S. and Dicks, H. 1998. Determination of surface properties and flow characteristics of salbutamol sulphate, before and after micronisation. International journal of pharmaceutics, 172, 89-96.
83. Fehrenbach, H. 2001. Alveolar epithelial type II cell: defender of the alveolus revisited. Respiratory Research, 2, 33-46.
84. Ferrari, F., Cocconi, D., Bettini, R., Giordano, F., Santi, P., Tobyn, M., Price, R., Young, P., Caramella, C. and Colombo, P. 2004. The surface roughness of lactose particles can be modulated by wet-smoothing using a high-shear mixer. AAPS PharmSciTech, 5, 69-74.
85. Finkbeiner, W.E. 1999. Physiology and pathology of tracheobronchial glands. Respiration physiology, 118, 77-83.
86. Flament, M.P., Leterme, P. and Gayot, A. 2004. The influence of carrier roughness on adhesion, content uniformity and the in vitro deposition of terbutaline sulphate from dry powder inhalers. International journal of pharmaceutics, 275, 201-209.
87. Fonner Jr, D.E., Banker, G.S. and Swarbrick, J. 2006. Micromeritics of granular pharmaceutical solids II. Factors involved in the sieving of pharmaceutical granules. Journal of pharmaceutical sciences, 55, 576-580.
88. Fowkes, F.M. 1964. Attractive forces at interfaces. Industrial and Engineering Chemistry, 56, 40-52.
89. French, D.L., Edwards, D.A. and Niven, R.W. 1996. The influence of formulation on emission, deaggregation and deposition of dry powders for inhalation. Journal of Aerosol Science, 27, 769-783.
90. Frijlink, H.W. and de Boer, A.H. 2005. Trends in the technology-driven development of new inhalation devices. Drug Discovery Today: Technologies, 2, 47-57.
91. Frijlink, H.W. and De Boer, A.H. 2004. Dry powder inhalers for pulmonary drug delivery. Expert Opinion on Drug Delivery, 1, 67-86.
92. Fukuoka, E. and Kimura, S. 1992. Cohesion of particulates solids. VIII: Influence of particle shape on compression by tapping. Chemical and pharmaceutical bulletin, 40, 2805-2809.
93. Fults, K.A., Miller, I.F. and Hickey, A.J. 1997. Effect of particle morphology on emitted dose of fatty acid-treated disodium cromoglycate powder aerosols. Pharmaceutical development and technology, 2, 67-79.
94. Ganderton, D. 1992. The generation of respirable clouds from coarse powder aggregates. Journal of Biopharmaceutical Science, 3, 101-105.
95. Ganderton, D. and Kassem, N.M. 1994. Aerosol carriers. USP patent, 5376386
96. Ganderton, D. and Kassem, N.M. 1992. Dry powder inhalers. Advances in Pharmaceutical Sciences, 6, 165-191.
97. Gehr, P., Bachofen, M. and Weibel, E.R. 1978. The normal human lung: ultrastructure and morphometric estimation of diffusion capacity. Respiration physiology, 32, 121-140.
98. Gonda, I. Targeting by deposition. In: Hickey AJ. Pharmaceutical Inhalation Aerosol Technology. New York: Marcel Dekker; 1992; 61-82.
99. Gonda, I. 1981. Study of the effects of polydispersity of aerosols on regional deposition in the respiratory tract. Journal of Pharmacy and Pharmacology, 33, 52P-148.
100. Grzesiak, A.L., Lang, M., Kim, K. and Matzger, A.J. 2003. Comparison of the four anhydrous polymorphs of carbamazepine and the crystal structure of form I Supplementary material: X-ray crystallographic information file (CIF) of triclinic CBZ (form I) is available. Journal of pharmaceutical sciences, 92, 2260-2271.
101. Guchardi, R., Frei, M., John, E. and Kaerger, J.S. 2008. Influence of fine lactose and magnesium stearate on low dose dry powder inhaler formulations. International journal of pharmaceutics, 348, 10-17.
102. Guenette, E., Barrett, A., Kraus, D., Brody, R., Harding, L. and Magee, G. 2009. Understanding the effect of lactose particle size on the properties of DPI formulations using experimental design. International journal of pharmaceutics, 380, 80-88.
103. Harjunen, P., Lehto, V.P., Martimo, K., Suihko, E., Lankinen, T., Paronen, P. and Järvinen, K. 2002. Lactose modifications enhance its drug performance in the novel multiple dose Taifun® DPI. European Journal of Pharmaceutical Sciences, 16, 313-321.
104. Hausner, H.H. 1967. Friction conditions in a mass of metal powder. International journal of refractory and hard metals, 3, 7-13
105. Henck, J.O., Griesser, U.J. and Burger, A. 1997. Polymorphie von Arzneistoffen: Eine wirtschaftliche Herausforderung?= Polymorphism of drug substances/An economic challenge. Pharmazeutische Industrie, 59, 165-169.
106. Heng, P.W., Chan, L.W. and Lim, L.T. 2000. Quantification of the surface morphologies of lactose carriers and their effect on the in vitro deposition of salbutamol sulphate. Chemical and pharmaceutical bulletin-tokyo-, 48, 393-398.
107. Hensley, M.J., O'Cain, C.F., McFadden Jr., E.R. and Ingram Jr, R.H. 1978. Distribution of bronchodilatation in normal subjects: beta agonist versus atropine. Journal of applied physiology, 45, 778.
108. Hersey, J.A. 1975. Ordered mixing: a new concept in powder mixing practice. Powder Technology, 11, 41-44.
109. Heyder, J., Gebhart, J., Rudolf, G., Schiller, C.F. and Stahlhofen, W. 1986, "Deposition of particles in the human respiratory tract in the size range 0.005-15 [mu] m", Journal of Aerosol Science, vol. 17, no. 5, pp. 811-825.
110. Heyder, J., Gebhart, J., Stahlhofen W. Inhalation of aerosols: particle deposition and retention. In: Willeke K. Generation of Aerosols and Facilities for Exposure Experiments. Michigan: Ann Arbor Science; 1980; 65-103.
111. Hickey, A.J. and Concessio, N.M. 1997. Descriptors of irregular particle morphology and powder properties. Advanced Drug Delivery Reviews, 26, 29-40.
112. Hickey, A.J., Concessio, N.M. and VAN, O. 1994. Factors influencing the dispersion of dry powders as aerosols. Pharmaceutical Technology, 18, 58-58.
113. Hickey, A.J. and Martonen, T.B. 1993. Behavior of hygroscopic pharmaceutical aerosols and the influence of hydrophobic additives. Pharmaceutical research, 10, 1-7.
114. Hickey, AJ, Thompson, DC. Physiology of the airways. In: Hickey, AJ. Pharmaceutical inhalation aerosol technology. New York: Marcel Dekker; 1992; 1-27.
115. Hindle, M, Jashnani, RN, Byron, PR. Dose emissions from marketed inhalers: Influence of flow, volume and environment. In: Dalby RN, Byron PR, Farr SJ. Respiratory Drug Delivery IV. Buffalo Grove, IL, USA: Interpharm Press; 1994; 137-142.
116. Hinds, WC. Aerosol Technology: Properties, Behavior, and Measurement of Airborne Particles. 2nd edition. New York: John Willey and Sons; 1999.
117. Hinds, WC. Properties, Behavior and Measurement of Airborne Particles. 2nd edition. New York: Wiley-Interscience; 1982
118. Hooton, J.C., German, C.S., Allen, S., Davies, M.C., Roberts, C.J., Tendler, S.J.B. and Williams, P.M. 2003. Characterization of particle-interactions by atomic force microscopy: effect of contact area. Pharmaceutical research, 20, 508-514.
119. Hooton, J.C., Jones, M.D. and Price, R. 2006. Predicting the behavior of novel sugar carriers for dry powder inhaler formulations via the use of a cohesive-adhesive force balance approach. Journal of pharmaceutical sciences, 95, 1288-1297.
120. Hooton, J.C., Jones, M.D. and Price, R. 2005. The effect of the use of a cohesive drug when predicting performance of dry powder inhalation formulations through the cohesive adhesive balance technique. Proceedings of Drug Delivery to the Lungs, 16, 143-146.
121. Howarth, P.H. 2001. Why particle size should affect clinical response to inhaled therapy. Journal of Aerosol Medicine, 14, 27-34.
122. Iida, K., Hayakawa, Y., Okamoto, H., Danjo, K. and Leuenberger, H. 2003. Preparation of dry powder inhalation by surface treatment of lactose carrier particles. Chemical and pharmaceutical bulletin, 51, 1-5.
123. Iida, K., Leuenberger, H., Fueg, L.M., Muller-Walz, R., Okamoto, H. and Danjo, K. 2000. Effect of mixing of fine carrier particles on dry powder inhalation property of salbutamol sulfate (SS). Journal of the Pharmaceutical Society of Japan, 120, 113-119.
124. Ikegami, K., Kawashima, Y., Takeuchi, H., Yamamoto, H., Isshiki, N., Momose, D. and Ouchi, K. 2002. Improved inhalation behavior of steroid KSR-592 in vitro with Jethaler® by polymorphic transformation to needle-like crystals (β-form). Pharmaceutical research, 19, 1439-1445.
125. Islam, N., Stewart, P., Larson, I. and Hartley, P. 2004. Lactose surface modification by decantation: Are drug-fine lactose ratios the key to better dispersion of salmeterol xinafoate from lactose-interactive mixtures?. Pharmaceutical research, 21, 492-499.
126. Israelachvili, J. and Wennerström, H. 1996. Role of hydration and water structure in biological and colloidal interactions. Nature, 379, 219-225.
127. Jain, KK. Drug delivery systems-An overview. Jain PharmaBiotech, Basel, Switzerland: Methods in Molecular Biology; 2008.
128. Jashnani, R.N., Byron, P.R. and Dalby, R.N. 1995. Testing of dry powder aerosol formulations in different environmental conditions. International journal of pharmaceutics, 113, 123-130.
129. Jiang, R.G., Pan, W.S., Wang, C.L. and Liu, H. 2005. Use of recrystallized lactose as carrier for inhalation powder of interferon α 2b. Pharmazie, 60, 632-633.
130. Johnson, KL. Contact mechanics. 1st edition. New York; Cambridge University Press; 1985.
131. Johnson, K.L., Kendall, K. and Roberts, A.D. 1971. Surface energy and the contact of elastic solids. Proceedings of the Royal Society of London.Series A, Mathematical and Physical Sciences, 324, 301-313.
132. Jones, M.D., Harris, H., Hooton, J.C., Shur, J., King, G.S., Mathoulin, C.A., Nichol, K., Smith, T.L., Dawson, M.L. and Ferrie, A.R. 2008a. An investigation into the relationship between carrier-based dry powder inhalation performance and formulation cohesive-adhesive force balances. European journal of pharmaceutics and biopharmaceutics, 69, 496-507.
133. Jones, M.D., Hooton, J.C., Dawson, M.L., Ferrie, A.R. and Price, R. 2008b. An investigation into the dispersion mechanisms of ternary dry powder inhaler formulations by the quantification of interparticulate forces. Pharmaceutical research, 25, 337-348.
134. Jones, M.D. and Price, R. 2006. The influence of fine excipient particles on the performance of carrier-based dry powder inhalation formulations. Pharmaceutical research, 23, 1665-1674.
135. Jones, M.D., Santo, J.G.F., Yakub, B., Dennison, M., Master, H. and Buckton, G. 2010. The relationship between drug concentration, mixing time, blending order and ternary dry powder inhalation performance. International journal of pharmaceutics, 391, 137-147.
136. Kaialy, W., Martin, G.P., Ticehurst, M.D., Momin, M.N. and Nokhodchi, A. 2010a. The enhanced aerosol performance of salbutamol from dry powders containing engineered mannitol as excipient. International journal of pharmaceutics, 392, 178-188
137. Kaialy, W., Momin, M.N., Ticehurst, M.D., Murphy, J. and Nokhodchi, A. 2010b. Engineered Mannitol as an alternative carrier to enhance deep lung penetration of salbutamol sulphate from dry powder inhaler. Colloids and Surfaces B: Biointerfaces, 79, 345-356.
138. Kaialy, W., Martin, G.P., Ticehurst, M.D., Royall, P., Mohammad, M.A., Murphy, J., Nokhodchi, A. 2011a. Characterisation and deposition studies of recrystallised lactose from binary mixtures of ethanol/butanol for improved drug delivery from dry powder inhalers. The AAPS Journal. 2011, 13, 30-43.
139. Kaialy, W., Ticehurst, M.D., Murphy, J., Nokhodchi, A. Improved aerosolization performance of salbutamol sulfate formulated with lactose crystallized from binary mixtures of ethanol-acetone. In press.
140. Karhu, M., Kuikka, J., Kauppinen, T., Bergström, K. and Vidgren, M. 2000. Pulmonary deposition of lactose carriers used in inhalation powders. International journal of pharmaceutics, 196, 95-103.
141. Karra, V.K. and Fuerstenau, D.W. 1977. The effect of humidity on the trace mixing kinetics in fine powders. Powder Technology, 16, 97-105.
142. Kassem, NM. Generation of deeply inspirable dry powders. Dry Powders PhD thesis, University of London; 1990
143. Kassem, N.M. and Ganderton, D. 1990. The influence of carrier surface on the characteristics of inspirable powder aerosols. Journal of Pharmacy and Pharmacology, 42, 11P.
144. Katainen, J., Paajanen, M., Ahtola, E., Pore, V. and Lahtinen, J. 2006. Adhesion as an interplay between particle size and surface roughness. Journal of colloid and interface science, 304, 524-529.
145. Kawashima, Y., Serigano, T., Hino, T., Yamamoto, H. and Takeuchi, H. 1998. Effect of surface morphology of carrier lactose on dry powder inhalation property of pranlukast hydrate. International journal of pharmaceutics, 172, 179-188.
146. Kendall, K. 1994. Adhesion: molecules and mechanics. Science, 263, 1720.
147. Khilnani, G.C. and Banga, A. 2008. Aerosol therapy. Indian Journal of Chest Diseases and Allied Sciences, 50, 209.
148. Kulvanich, P. and Stewart, P.J. 1987. The effect of particle size and concentration on the adhesive characteristics of a model drug-carrier interactive system. The Journal of pharmacy and pharmacology, 39, 673-678.
149. Kumar, P., Santosa, J.K., Beck, E. and Das, S. 2004. Direct-write deposition of fine powders through miniature hopper-nozzles for multi-material solid freeform fabrication. Rapid Prototyping Journal, 10, 14-23.
150. Labiris, N.R. and Dolovich, M.B. 2003. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. British journal of clinical pharmacology, 56, 588-599.
151. Lahav, M. and Leiserowitz, L. 2001. The effect of solvent on crystal growth and morphology. Chemical Engineering Science, 56, 2245-2254.
152. Lai, C.K., Holt, D., Leung, J.C., Cooney, C.L., Raju, G.K. and Hansen, P. 2001. Real time and noninvasive monitoring of dry powder blend homogeneity. AICHE Journal, 47, 2618-2622.
153. Lam, K.K. and Newton, J.M. 1992. Influence of particle size on the adhesion behaviour of powders, after application of an initial press-on force. Powder Technology, 73, 117-125.
154. Larhrib, H., Martin, G.P., Marriott, C. and Prime, D. 2003a. The influence of carrier and drug morphology on drug delivery from dry powder formulations. International journal of pharmaceutics, 257, 283-296.
155. Larhrib, H., Martin, G.P., Prime, D. and Marriott, C. 2003b. Characterisation and deposition studies of engineered lactose crystals with potential for use as a carrier for aerosolised salbutamol sulfate from dry powder inhalers. European Journal of Pharmaceutical Sciences, 19, 211-221.
156. Larhrib, H., Zeng, X.M., Martin, G.P., Marriott, C. and Pritchard, J. 1999. The use of different grades of lactose as a carrier for aerosolised salbutamol sulphate. International journal of pharmaceutics, 191, 1-14.
157. Lechuga-Ballesteros, D. and Kuo, M.C. 2001, "Dry powder compositions having improved dispersivity", WO, vol. 1, pp. 32144.
158. Lee, T.H. and Lin, S.Y. 2004. Microspectroscopic FT-IR mapping system as a tool to assess blend homogeneity of drug-excipient mixtures. European journal of pharmaceutical sciences, 23, 117-122.
159. Levins, J.M. and Vanderlick, T.K. 1995. Impact of roughness on the deformation and adhesion of a rough metal and smooth mica in contact. The Journal of physical chemistry, 99, 5067-5076.
160. Li, Q., Rudolph, V. and Peukert, W. 2006. London-van der Waals adhesiveness of rough particles. Powder Technology, 161, 248-255.
161. Lippmann, M. and Schlesinger, R.B. 1984. Interspecies comparisons of particle deposition and mucociliary clearance in tracheobronchial airways. Journal of Toxicology and Environmental Health, Part A, 13, 441-469.
162. Lippmann, M., Yeates, D.B. and Albert, R.E. 1980. Deposition, retention, and clearance of inhaled particles. British medical journal, 37, 337-362.
163. Lobo, J.M., Schiavone, H., Palakodaty, S., York, P., Clark, A. and Tzannis, S.T. 2005. SCF-engineered powders for delivery of budesonide from passive DPI devices. Journal of pharmaceutical sciences, 94, 2276-2288.
164. Louey, M.D., Mulvaney, P. and Stewart, P.J. 2001. Characterisation of adhesional properties of lactose carriers using atomic force microscopy. Journal of pharmaceutical and biomedical analysis, 25, 559-567.
165. Louey, M.D., Razia, S. and Stewart, P.J. 2003. Influence of physico-chemical carrier properties on the in vitro aerosol deposition from interactive mixtures. International journal of pharmaceutics, 252, 87-98.
166. Louey, M.D. and Stewart, P.J. 2002. Particle interactions involved in aerosol dispersion of ternary interactive mixtures. Pharmaceutical research, 19, 1524-1531.
167. Louey, M.D., Van Oort, M. and Hickey, A.J. 2004b. Aerosol dispersion of respirable particles in narrow size distributions using drug-alone and lactose-blend formulations. Pharmaceutical research, 21, 1207-1213.
168. Louey, M.D., Van Oort, M. and Hickey, A.J. 2004a. Aerosol dispersion of respirable particles in narrow size distributions produced by jet-milling and spray-drying techniques. Pharmaceutical research, 21, 1200-1206.
169. Lowell, S. Introduction to powder surface area. New York: NY: John Wiley and Sons; 1979.
170. Lucas, P., Anderson, K., Potter, U.J. and Staniforth, J.N. 1999. Enhancement of small particle size dry powder aerosol formulations using an ultra low density additive. Pharmaceutical research, 16, 1643-1647.
171. Lucas, P., Anderson, K. and Staniforth, J.N. 1998. Protein deposition from dry powder inhalers: fine particle multiplets as performance modifiers. Pharmaceutical research, 15, 562-569.
172. Maa, Y.F., Nguyen, P.A., Sweeney, T., Shire, S.J. and Hsu, C.C. 1999. Protein inhalation powders: spray drying vs spray freeze drying. Pharmaceutical research, 16, 249-254.
173. Maa, Y.F. and Prestrelski, S.J. 2000. Biopharmaceutical powders particle formation and formulation considerations. Current Pharmaceutical Biotechnology, 1, 283-302.
174. Mackin, L.A., Rowley, G. and Fletcher, E.J. 1997. An investigation of carrier particle type, electrostatic charge and relative humidity on in-vitro drug deposition from dry powder inhaler formulations. Pharmaceutical .Science, 3, 583-586.
175. Malcolmson, R.J. and Embleton, J.K. 1998. Dry powder formulations for pulmonary delivery. Pharmaceutical science and technology today, 1, 394-398.
176. Martonen, T. and Yang, Y. 1996. Deposition mechanics of pharmaceutical particles in human airways. Lung biology in health and disease, 94, 3-27.
177. Martonen, T.B., Katz, I., Fults, K. and Hickey, A.J. 1992. Use of analytically defined estimates of aerosol respirable fraction to predict lung deposition patterns. Pharmaceutical research, 9, 1634-1639.
178. Martonen, T.B. and Katz, I.M. 1993, "Deposition patterns of aerosolized drugs within human lungs: effects of ventilatory parameters", Pharmaceutical research, vol. 10, no. 6, pp. 871-878.
179. Maugis, D. 1996. On the contact and adhesion of rough surfaces. Journal of Adhesion Science and Technology, 10, 161-175.
180. Maynard, A.D. and Maynard, R.L. 2002. A derived association between ambient aerosol surface area and excess mortality using historic time series data. Atmospheric Environment, 36, 5561-5567.
181. Mbanga kendeck, P. 1979. Etude de l'homogeneité des mélanges de poudres; nouvelles hypothèses de formulation. Thesis of Ph.D. in Pharmacy, Lille University, France.
182. Meekes, H., Boerrigter, S.X.M., Hollander, F.F.A. and Bennema, P. 2003. Needle crystal morphology explained. Chemical Engineering and Technology, 26, 256-261.
183. Melani, A.S., Zanchetta, D., Barbato, N., Sestini, P., Cinti, C., Canessa, P.A., Aiolfi, S. and Neri, M. 2004. Inhalation technique and variables associated with misuse of conventional metered-dose inhalers and newer dry powder inhalers in experienced adults. Annals of Allergy, Asthma and Immunology, 93, 439-446.
184. Mitchell, D.M., Solomon, M.A., Tolfree, S.E., Short, M. and Spiro, S.G. 1987. Effect of particle size of bronchodilator aerosols on lung distribution and pulmonary function in patients with chronic asthma. British medical journal, 42, 457-461.
185. Mitchell, J.P. and Nagel, M.W. 2003. Cascade impactors for the size characterization of aerosols from medical inhalers: their uses and limitations. Journal of Aerosol Medicine, 16, 341-377.
186. Moulton, B. and Zaworotko, M.J. 2001. From molecules to crystal engineering: supramolecular isomerism and polymorphism in network solids. Chem.Rev, 101, 1629-1658.
187. Mukaida, K.I. 1981. Density measurement of small porous particles by mercury porosimetry. Powder Technology, 29, 99-107.
188. Mullins, M.E., Michaels, L.P., Menon, V., Locke, B. and Ranade, M.B. 1992. Effect of geometry on particle adhesion. Aerosol Science and Technology, 17, 105-118.
189. Murakoshi, H., Saotome, T., Fujii, Y., Ozeki, T., Takashima, Y., Yuasa, H. and Okada, H. 2005. Effect of physical properties of carrier particles on drug emission from a dry powder inhaler device. Journal of drug delivery science and technology, 15, 223-226.
190. Musante, C.J., Schroeter, J.D., Rosati, J.A., Crowder, T.M., Hickey, A.J. and Martonen, T.B. 2002. Factors affecting the deposition of inhaled porous drug particles. Journal of pharmaceutical sciences, 91, 1580-1590.
191. Muzzio, F.J., Robinson, P., Wightman, C. and Brone, D. 1997. Sampling practices in powder blending. International journal of pharmaceutics, 155, 153-178.
192. Nakate, T., Yoshida, H., Ohike, A., Tokunaga, Y., Ibuki, R. and Kawashima, Y. 2004. Formulation development of inhalation powders for FK888 with carrier lactose using Spinhaler® and its absorption in healthy volunteers. Journal of Controlled Release, 97, 19-29.
193. Neumann, B.S. 1967. The flow properties of powders. Advances in Pharmaceutical Sciences, 2, 191-221.
194. Newman, S.P., Hollingworth, A. and Clark, A.R. 1994. Effect of different modes of inhalation on drug delivery from a dry powder inhaler. International journal of pharmaceutics, 102, 127-132.
195. Newman, S.P., Moren, F., Trofast, E., Talaee, N. and Clarke, S.W. 1989. Deposition and clinical efficacy of terbutaline sulphate from Turbuhaler, a new multi-dose powder inhaler. European Respiratory Journal, 2, 247-252.
196. Notter, R.H. 2000b. Discovery of endogenous lung surfactant and overview of its metabolism and actions. Bland RD, Coalson JJ, eds Lung Surfactants: Basic Science and Clinical Applications, Lung Biology in Health and Disease Series, 149, 119-149.
197. Notter, R.H. 2000a. Functional composition and component biophysics of endogenous lung surfactant. Lung Surfactants: Basic Science and Clinical Applications, 149, 171-206.
198. Otsuka, A., Iida, K., Danjo, K. and Sunada, H. 1988. Measurement of the adhesive force between particles of powdered materials and a glass substrate by means of the impact separation method. III: Effect of particle shape and surface asperity. Chemical and pharmaceutical bulletin, 36, 741-749.
199. Paajanen, M., Katainen, J., Raula, J., Kauppinen, E.I. and Lahtinen, J. 2009. Direct evidence on reduced adhesion of Salbutamol sulphate particles due to L-leucine coating. Powder Technology, 192, 6-11.
200. Patton, J.S., Bukar, J. and Nagarajan, S. 1999. Inhaled insulin1. Advanced Drug Delivery Reviews, 35, 235-247.
201. Pell, M. and Dunson, J.B. Gas-solid operations and equipment. Heat Transfer, 17, 10.
202. Phalen, R.F., Yeh, H.C. and Prasad, S.B. 1995. Morphology of the respiratory tract. Concepts in Inhalation Toxicology, 2, 129-149.
203. Philip, V.A., Mehta, R.C., Mazumder, M.K. and DeLuca, P.P. 1997. Effect of surface treatment on the respirable fractions of PLGA microspheres formulated for dry powder inhalers. International journal of pharmaceutics, 151, 165-174.
204. Phipps, R.J. 1981. The airway mucociliary system. International review of physiology, 23, 213-260.
205. Pilcer, G. New highly effective dry powder tobramycin formulations for inhalation in the treatment of cystic fibrosis. Universite libre de Bruxelles Institut de Pharmacie Laboratoire de Pharmacie Gal nique et de Biopharmacie; 2008.
206. Podczeck, F. 1999. The influence of particle size distribution and surface roughness of carrier particles on the in vitro properties of dry powder inhalations. Aerosol Science and Technology, 31, 301-321.
207. Podczeck, F. 1998. The relationship between physical properties of lactose monohydrate and the aerodynamic behaviour of adhered drug particles. International journal of pharmaceutics, 160, 119-130.
208. Podczeck, F. 1997. Optimization of the operation conditions of an Andersen-Cascade impactor and the relationship to centrifugal adhesion measurements to aid the development of dry powder inhalations. International journal of pharmaceutics, 149, 51-61.
209. Podczeck, F. and Mia, Y. 1996c. The influence of particle size and shape on the angle of internal friction and the flow factor of unlubricated and lubricated powders. International journal of pharmaceutics, 144, 187-194.
210. Podczeck, F. and Newton, J.M. 1995. Development of an ultracentrifuge technique to determine the adhesion and friction properties between particles and surfaces. Journal of pharmaceutical sciences, 84, 1067-1071.
211. Podczeck, F., Newton, J.M. and James, M.B. 1996b. The adhesion force of micronized salmeterol xinafoate particles to pharmaceutically relevant surface materials. Journal of Physics D: Applied Physics, 29, 1878.
212. Podczeck, F., Newton, J.M. and James, M.B. 1996a. The influence of constant and changing relative humidity of the air on the autoadhesion force between pharmaceutical powder particles. International journal of pharmaceutics, 145, 221-229.
213. Price, R., Young, P.M., Edge, S. and Staniforth, J.N. 2002. The influence of relative humidity on particulate interactions in carrier-based dry powder inhaler formulations. International journal of pharmaceutics, 246, 47-59.
214. Price, A.H. and Clissold, S.P. 1989. Salbutamol in the 1980s. A reappraisal of its clinical efficacy. Drugs, 38, 77-122.
215. Rabbani, N.R. and Seville, P.C. 2005. The influence of formulation components on the aerosolisation properties of spray-dried powders. Journal of Controlled Release, 110, 130-140.
216. Rees, P.J., Clark, T.J. and Moren, F. 1982. The importance of particle size in response to inhaled bronchodilators. European journal of respiratory diseases.Supplement, 119, 73-78.
217. Riddle Jr, F.L. and Fowkes, F.M. 1990. Spectral shifts in acid-base chemistry. 1. van der Waals contributions to acceptor numbers. Journal of the American Chemical Society, 112, 3259-3264.
218. Ridgway, K. and Rupp, R. 1969. The effect of particle shape on powder properties. The Journal of pharmacy and pharmacology, 21, Suppl:30S+.
219. Rodriguez-Spong, B., Price, C.P., Jayasankar, A., Matzger, A.J. and Rodriguez-Hornedo, N. 2004. General principles of pharmaceutical solid polymorphism: A supramolecular perspective. Advanced Drug Delivery Reviews, 56, 241-274.
220. Ross, MH, Romrell, LJ, Kaye, GI. Respiratory system. In: Ross, MH, Romrell LJ, Kaye GI. Histology-A textbook and atlas. Baltimore: Wiliams and Wilkins; 1995; 530-557.
221. Rudolf, G., Gebhart, J., Heyder, J., Schiller, C.F. and Stahlhofen, W. 1986. An empirical formula describing aerosol deposition in man for any particle size. Journal of Aerosol Science, 17, 350-355.
222. Saint-Lorant, G., Leterme, P., Gayot, A. and Flament, M.P. 2007. Influence of carrier on the performance of dry powder inhalers. International journal of pharmaceutics, 334, 85-91.
223. Saleki-Gerhardt, A., Ahlneck, C. and Zografi, G. 1994. Assessment of disorder in crystalline solids. International journal of pharmaceutics, 101, 237-247.
224. Schiavone, H., Palakodaty, S., Clark, A., York, P. and Tzannis, S.T. 2004. Evaluation of SCF-engineered particle-based lactose blends in passive dry powder inhalers. International journal of pharmaceutics, 281, 55-66.
225. Schlesinger, R.B. 1995. Deposition and clearance of inhaled particles. Concepts in inhalation toxicology, 2, 1-224.
226. Schutte, B.C. and McCray Jr, P.B. 2002. β-Defensins in lung host defense. Annual Review of Physiology, 64, 709-748.
227. Sethuraman, V.V. and Hickey, A.J. 2002. Powder properties and their influence on dry powder inhaler delivery of an antitubercular drug. AAPS PharmSciTech, 3, 7-16.
228. Shekunov, B.Y., Feeley, J.C., Chow, A.H.L., Tong, H.H.Y. and York, P. 2003. Aerosolisation behaviour of micronised and supercritically-processed powders. Journal of Aerosol Science, 34, 553-568.
229. Shinohara, K. Rheological property of particulate solids. In Fayed ME, Otten L. Handbook of Powder Science and Technology. Van Nostrand Reinhold, New York: Journal of Pharmaceutical Sciences; 1984; 396-404.
230. Smith, K.J., Chan, H.A.K.K.I.M. and Brown, K.F. 1998. Influence of flow rate on aerosol particle size distributions from pressurized and breath-actuated inhalers. Journal of Aerosol Medicine, 11, 231-245.
231. Smyth, H.D.C. and Hickey, A.J. 2005. Carriers in drug powder delivery: implications for inhalation system design. American Journal of Drug Delivery, 3, 117-132.
232. Snow, RH, Allen, T, Ennis, BJ, Litster, JD. Size reduction and size enlargement. In: Green DW. Perry's chemical engineer's handbook. New York: McGraw-Hill; 1984; Section 20.
233. Soltani, M., Ahmadi, G., Bayer, R.G. and Gaynes, M.A. 1995. Particle detachment mechanisms from rough surfaces under substrate acceleration. Journal of Adhesion Science and Technology, 9, 453-473.
234. Stahlhofen, W., Gebhart, J. and Heyder, J. 1980. Experimental determination of the regional deposition of aerosol particles in the human respiratory tract. American Industrial Hygiene Association Journal, 41, 385-398.
235. Staniforth, J.N., Rees, J.E., Lai, F.K. and Hersey, J.A. 1982. Interparticle forces in binary and ternary ordered powder mixes. The Journal of pharmacy and pharmacology, 34, 141-145.
236. Stanley-Wood, NG, Zolfaghari, ME, Sarrafi, M. Correlations Between Size. Shape And Flow Properties Of Cohesive And Free Flowing Powders. In: Lloyd PJ. Particle Size Analysis. New York: John Wiley and Sons; 1988; 189-197.
237. Steckel, H., Borowski, M., Eskandar, F. and Villax, P. 2004. Solid dosage Selecting Lactose for a Capsule-Based Dry Powder Inhaler. Pharmaceutical technology europe, 16, 23-36.
238. Steckel, H. and Müller, B.W. 1997. In vitro evaluation of dry powder inhalers II: influence of carrier particle size and concentration on in vitro deposition. International journal of pharmaceutics, 154, 31-37.
239. Stone, K.C., Mercer, R.R., Gehr, P., Stockstill, B. and Crapo, J.D. 1992. Allometric relationships of cell numbers and size in the mammalian lung. American journal of respiratory cell and molecular biology, 6, 235-243.
240. Suarez, S. and Hickey, A.J. 2000. Drug properties affecting aerosol behavior. Respiratory care, 45, 652-666.
241. Sudah, O.S., Coffin-Beach, D. and Muzzio, F.J. 2002. Effects of blender rotational speed and discharge on the homogeneity of cohesive and free-flowing mixtures. International journal of pharmaceutics, 247, 57-68.
242. Svarovsky, L. Methods of measuring the physical properties of bulk powders. In: Svarovsky, L. Powder testing guide. London: Elsevier; 1987; 16-36.
243. Swaminathan, V. and Kildsig, D.O. 2000. The effect of particle morphology on the physical stability of pharmaceutical powder mixtures: the effect of surface roughness of the carrier on the stability of ordered mixtures. Drug development and industrial pharmacy, 26, 365-373.
244. Swift, D.L. and Proctor, D.F. 1982. Human respiratory deposition of particles during oronasal breathing. Atmospheric Environment (1967), 16, 2279-2282.
245. Swift, D.L. 1980. Aerosols and humidity therapy. Generation and respiratory deposition of therapeutic aerosols. The American Review of Respiratory Disease, 122, 71-77.
246. Tabor, D. 1977. Surface forces and surface interactions. Journal of colloid and interface science, 58, 2-13.
247. Tarara, TE, Weers, J, Dellamary, L. Engineered powders for inhalation. In: Dalby RN, Byron PR, Farr SJ, Peart J. Respiratory Drug Delivery VII. Buffalo Grove, IL: Serentec Press, Raleigh; 2000; 413-416.
248. Taulelle, P., Astier, J.P., Hoff, C., Pepe, G. and Veesler, S. 2006. Pharmaceutical compound crystallization: Growth mechanism of needle-like crystals. Chemical Engineering and Technology, 29, 239-246.
249. Tee, S.K., Marriott, C., Zeng, X.M. and Martin, G.P. 2000. The use of different sugars as fine and coarse carriers for aerosolised salbutamol sulphate. International journal of pharmaceutics, 208, 111-123.
250. Telko, M.J. and Hickey, A.J. 2005. Dry powder inhaler formulation. Respiratory care, 50, 1209.
251. Telko, M.J., Kujanpää, J. and Hickey, A.J. 2007. Investigation of triboelectric charging in dry powder inhalers using electrical low pressure impactor (ELPI™)". International journal of pharmaceutics, 336, 352-360.
252. Tezky, T., Holquist, C. and RPh, U. 2005. FDA Safety Page: Misadministration of capsules for inhalation. Drug Topics, 4, 4.
253. Thalberg, K., Lindholm, D. and Axelsson, A. 2004. Comparison of different flowability tests for powders for inhalation. Powder Technology, 146, 206-213.
254. Thompson, P.J. 1998. Drug delivery to the small airways. American journal of respiratory and critical care medicine, 157, S199.
255. Ticehurst, M., Rowe, R. and York, P. 1994. Determination of the surface properties of two batches of salbutamol sulphate by inverse gas chromatography. International journal of pharmaceutics, 111, 241-249.
256. Timsina, M.P., Martin, G.P., Marriott, C., Ganderton, D. and Yianneskis, M. 1994. Drug delivery to the respiratory tract using dry powder inhalers. International journal of pharmaceutics, 101, 1-13.
257. Traini, D., Young, P.M., Thielmann, F. and Acharya, M. 2008. The Influence of Lactose Pseudopolymorphic Form on Salbutamol Sulfate-Lactose Interactions in DPI Formulations. Drug development and industrial pharmacy, 34, 992-1001.
258. Tsukada, M., Irie, R., Yonemochi, Y., Noda, R., Kamiya, H., Watanabe, W. and Kauppinen, E.I. 2004. Adhesion force measurement of a DPI size pharmaceutical particle by colloid probe atomic force microscopy. Powder Technology, 141, 262-269.
259. Usmani, O.S., Biddiscombe, M.F., Nightingale, J.A., Underwood, S.R. and Barnes, P.J. 2003. Effects of bronchodilator particle size in asthmatic patients using monodisperse aerosols. Journal of applied physiology, 95, 2106.
260. USP pharmacopeia 2003. The official compendia of standards, USP 26/NF 21; united states pharmacopeial conventio, inc: Rockville, MD. <601> aerosols, 2114-2123.
261. USP pharmacopeia 1995. The National Formulary, United States Pharmacopeial Convention, Inc., Rockville, MD.Aerosols (601), 23 (NF 18), 1760-1767.
262. Van Campen, L., Amidon, G.L. and Zografi, G. 2006. Moisture sorption kinetics for water-soluble substances I: Theoretical considerations of heat transport control. Journal of pharmaceutical sciences, 72, 1381-1388.
263. Van Campen, L, Venthoye, G. Inhalation, dry powder. In: Swarbrick J, Boylan JC. Encyclopedia of pharmaceutical technology. New York: Marcel Dekker Inc; 2002; 1529-1544.
264. Vanbever, R., Mintzes, J.D., Wang, J., Nice, J., Chen, D., Batycky, R., Langer, R. and Edwards, D.A. 1999. Formulation and physical characterization of large porous particles for inhalation. Pharmaceutical research, 16, 1735-1742.
265. Vanderbist, F., Baudier, P. and Maes, P. 2006. Dry power inhaler excipient, process for its preparation and pharmaceutical compositions containing it. United States Patent, 7090870
266. Velaga, S.P., Bergh, S. and Carlfors, J. 2004. Stability and aerodynamic behaviour of glucocorticoid particles prepared by a supercritical fluids process. European Journal of Pharmaceutical Sciences, 21, 501-509.
267. Vidgren, M.T., Vidgren, P.A. and Paronen, T.P. 1987. Comparison of physical and inhalation properties of spray-dried and mechanically micronized disodium cromoglycate. International journal of pharmaceutics, 35, 139-144.
268. Vidgren, P., Silvasti, M., Vidgren, M., Paronen, P., Tukiainen, H. and Lehti, H. 1991. In vitro inhalation behaviour and therapeutical response of salbutamol particles administered from two metered dose aerosols. Die Pharmazie, 46, 41-43.
269. Visser, J. 1989. Van der Waals and other cohesive forces affecting powder fluidization. Powder Technology, 58, 1-10.
270. Wall, D.A. 1995. Pulmonary absorption of peptides and proteins. Drug delivery, 2, 1-20.
271. Wang, J.U.E., Ben-jebria, A. and Edwards, D.A. 1999. Inhalation of estradiol for sustained systemic delivery. Journal of Aerosol Medicine, 12, 27-36.
272. Watanabe, M., Ozeki, T., Shibata, T., Murakoshi, H., Takashima, Y., Yuasa, H. and Okada, H. 2003. Effect of shape of sodium salicylate particles on physical property and in vitro aerosol performance of granules prepared by pressure swing granulation method. AAPS PharmSciTech, 4, 506-513.
273. Weibel, E.R. 1965. Morphometry of the human lung. Anesthesiology, 26, 367.
274. Weiler, C., Egen, M., Trunk, M. and Langguth, P. 2009. Force control and powder dispersibility of spray dried particles for inhalation. Journal of pharmaceutical sciences, 99, 303-316.
275. Weyhers, H., Mehnert, W. and Müller, R.H. 1996. Analysis of particle size distribution of micronized lactose by laser diffractometry. Pharmazeutische Industrie, 58, 354-357.
276. Wong, L.W. and Pilpel, N. 1990. Effect of particle shape on the mixing of powders. The Journal of pharmacy and pharmacology, 42, 1-6.
277. York, P. 1994. Powdered raw materials: Characterizing batch uniformity. Respiratory Drug Delivery, 4, 83-91.
278. Young, P.M., Cocconi, D., Colombo, P., Bettini, R., Price, R., Steele, D.F. and Tobyn, M.J. 2002. Characterization of a surface modified dry powder inhalation carrier prepared by" particle smoothing. Journal of Pharmacy and Pharmacology, 54, 1339-1344.
279. Young, P.M., Edge, S., Traini, D., Jones, M.D., Price, R., El-Sabawi, D., Urry, C. and Smith, C. 2005. The influence of dose on the performance of dry powder inhalation systems. International journal of pharmaceutics, 296, 26-33.
280. Young, P.M., Sung, A., Traini, D., Kwok, P., Chiou, H. and Chan, H.K. 2007. Influence of humidity on the electrostatic charge and aerosol performance of dry powder inhaler carrier based systems. Pharmaceutical research, 24, 963-970.
281. Zanen, P., Go, L.T. and Lammers, J.W. 1996. Optimal particle size for beta 2 agonist and anticholinergic aerosols in patients with severe airflow obstruction. British medical journal, 51, 977.
282. Zanen, P., Go, L.T. and Lammers, J.W.J. 1995. The optimal particle size for parasympathicolytic aerosols in mild asthmatics. International journal of pharmaceutics, 114, 111-115.
283. Zanen, P., Go, L.T. and Lammers, J.W.J. 1994. The optimal particle size for [beta]-adrenergic aerosols in mild asthmatics. International journal of pharmaceutics, 107, 211-217.
284. Zeng, XM, Martin, GP, Marriott, C. Particulate interactions in dry powder formulations for inhalation. London: Taylor and Francis; 2001a.
285. Zeng, X.M., Martin, G.P., Marriott, C. and Pritchard, J. 2001c. Lactose as a carrier in dry powder formulations: the influence of surface characteristics on drug delivery. Journal of pharmaceutical sciences, 90, 1424-1434.
286. Zeng, X.M., Martin, G.P., Marriott, C. and Pritchard, J. 2001b. The use of lactose recrystallised from carbopol gels as a carrier for aerosolised salbutamol sulphate. European Journal of Pharmaceutics and Biopharmaceutics, 51, 55-62.
287. Zeng, X.M., Martin, G.P., Marriott, C. and Pritchard, J. 2000a. The influence of carrier morphology on drug delivery by dry powder inhalers. International journal of pharmaceutics, 200, 93-106.
288. Zeng, X.M., Martin, G.P., Tee, S.K., Ghoush, A.A. and Marriott, C. 1999. Effects of particle size and adding sequence of fine lactose on the deposition of salbutamol sulphate from a dry powder formulation. International journal of pharmaceutics, 182, 133-144.
289. Zeng, X.M., Martin, G.P., Tee, S.K. and Marriott, C. 1998. The role of fine particle lactose on the dispersion and deaggregation of salbutamol sulphate in an air stream in vitro. International journal of pharmaceutics, 176, 99-110.
290. Zeng, X.M., Pandhal, K.H. and Martin, G.P. 2000b. The influence of lactose carrier on the content homogeneity and dispersibility of beclomethasone dipropionate from dry powder aerosols. International journal of pharmaceutics, 197, 41-52.
291. Zeng, X.M., Tee, S.K., Martin, G.P. and Marriott, C. 1996. Improving the delivery efficiency of dry powder inhalers (DPIs) by adding fine carrier particles to powder formulations. Thorax, 51, 195.
292. Zimon, A.D. 1982. Adhesion, molecular interaction and surface roughness. Adhesion of dust and powder, 2, 46-47.
293. Zimon, A. Adhesion of Dust and Powder, translated from Russian by M. Corn. 2nd edition. New York: Adhesion Science and Technology; 1969.